J&J ‘s Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) received Priority Review as a potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results